Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2022-10-18
DOI
10.1200/jco.22.01207
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Toxicity and efficacy of chronomodulated chemotherapy: a systematic review
- (2022) Markella I Printezi et al. LANCET ONCOLOGY
- The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas
- (2021) Benoit You et al. CANCER TREATMENT REVIEWS
- Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial.
- (2021) Benoit You et al. JOURNAL OF CLINICAL ONCOLOGY
- The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review
- (2021) Ambroise Lauby et al. Cancers
- CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial
- (2020) Benoît You et al. CLINICAL CANCER RESEARCH
- PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
- (2020) William P. Tew et al. JOURNAL OF CLINICAL ONCOLOGY
- 847P The prognostic value of chemosensitivity, estimated by the modeled CA-125 KELIM, in ovarian cancer patients treated with neo-adjuvant chemotherapy in the Netherlands
- (2020) L. Van Wagensveld et al. ANNALS OF ONCOLOGY
- Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study
- (2019) Olivier Colomban et al. CLINICAL CANCER RESEARCH
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
- (2019) Krishnansu S. Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
- (2019) Andrew R Clamp et al. LANCET
- Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials
- (2018) Glenn Heller et al. JOURNAL OF CLINICAL ONCOLOGY
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
- (2018) Willemien J. van Driel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Alexi A. Wright et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection
- (2013) F. Collinson et al. CLINICAL CANCER RESEARCH
- The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a GINECO-GCIG study)
- (2013) Benoit You et al. GYNECOLOGIC ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now